刘雨晴,袁淑敏,祁晓星,等.不同剂量安罗替尼联合PD-1单抗治疗晚期非小细胞肺癌的疗效和安全性分析[J].肿瘤学杂志,2023,29(5):407-411. |
不同剂量安罗替尼联合PD-1单抗治疗晚期非小细胞肺癌的疗效和安全性分析 |
Efficacy and Safety of Different Doses of Anlotinib Combined with PD-1 Monoclonal Antibody in Treatment of Non-Small Cell Lung Cancer |
投稿时间:2023-01-19 |
DOI:10.11735/j.issn.1671-170X.2023.05.B010 |
|
|
中文关键词: 非小细胞肺癌 安罗替尼 免疫检查点抑制剂 疗效 安全性 |
英文关键词:non-small cell lung cancer Anlotinib immune checkpoint inhibitors efficacy safety |
基金项目:河南省医学科技攻关计划联合共建项目(LHGJ20200535);河南省中青年卫生健康科技创新优秀人才培养项目(YXKC2022045) |
|
摘要点击次数: 791 |
全文下载次数: 258 |
中文摘要: |
摘 要:[目的] 探讨不同剂量安罗替尼联合PD-1单抗治疗晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)的疗效和安全性。[方法] 回顾分析不同剂量安罗替尼(8、10和12 mg,1次/d,服2周,停1周)联合PD-1单抗作为二线或以上治疗69例晚期NSCLC的疗效和安全性。观察指标包括:无进展生存期(progression-free survival,PFS)、总生存期(overall survival,OS)、客观缓解率(objective response rate,ORR)、疾病控制率(disease control rate,DCR)和安全性。[结果] 较低剂量安罗替尼组(8或10 mg)具有比常规剂量组(12 mg)更优的PFS(NR vs 10.3个月,HR=0.43,95%CI:0.202~0.929,P=0.024)和OS(NR vs 19.0个月,HR=0.33,95%CI:0.108~0.980,P=0.045)。较低剂量安罗替尼联合PD-1单抗的ORR、DCR和疾病进展率( progressive disease rate,PDR)分别为37.5%(15/40)、85.0%(34/40)和15.0%(6/40),常规剂量组分别为20.7%(6/29)、62.1%(18/29)和37.9%(11/29)(χ2=1.67,P=0.196;χ2=6.10,P=0.014;χ2=4.76,P=0.029)。不良反应方面,与常规剂量组相比,较低剂量组手足综合征(7.5% vs 10.3%)和高血压(5.0% vs 10.3%)的发生率略低,但差异没有统计学意义。[结论] 较低剂量安罗替尼与PD-1单抗联合二线或以上治疗晚期NSCLC具有更优的疗效和安全性。 |
英文摘要: |
Abstract:[Objective] To investigate the efficacy and safety of different doses of Anlotinib combined with PD-1 monoclonal antibody in the treatment of advanced non-small cell lung cancer(NSCLC). [Methods] Sixty-nine patients with advanced NSCLC who received different doses of Anlotinib(8, 10 and 12 mg qd for 2 weeks with one-week interval) combined with PD-1 monoclonal antibody as a second-line or above treatment were included in the analysis. The outcome measures included progression-free survival(PFS), overall survival(OS), objective response rate(ORR), disease control rate(DCR) and safety. [Results] The lower dose group(8 or 10 mg) had better PFS(NR vs 10.3 months, HR=0.43, 95%CI:0.202~0.929, P=0.024) and OS(NR vs 19.0 months, HR=0.33, 95%CI: 0.108~0.980, P=0.045) than the conventional dose group(12 mg). The ORR, DCR and disease progression rate(PDR) of lower dose Anlotinib combined with PD-1 monoclonal antibody were 37.5%(15/40), 85.0%(34/40) and 15.0%(6/40), respectively, and those in conventional dose group were 20.7%(6/29), 62.1%(18/29) and 37.9%(11/29), respectively(χ2=1.67, P=0.196; χ2=6.10, P=0.014; χ2=4.76, P=0.029). The incidence of hand foot syndrome(7.5% vs 10.3%) and hypertension(5.0% vs 10.3%) in the lower dose group had a decreasing trend, but there was no significant difference between two groups. [Conclusion] Lower dose of Anlotinib combined with PD-1 monoclonal antibody is effective and safe in the treatment of advanced NSCLC. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |